A ChemTek, located at 100 Barber Ave, Worcester MA, provides chemicals, analytical, purification products and services to world-wide pharmaceutical researchers in an Easy, Economic, Efficient& Express way. The major products include Amino Acids, Bioactive Reference Compounds, Nature Products, Building Blocks; HPLC/prep-HPLC/flash columns, chromatography systems, TLC, silica gel, syringe filters, vials etc.
Founded in 1981 and based in the city of Paris (France), Prothia has established itself in the medical device and equipment universe and acquired particular understanding of cardiovascular, perinatal and rehabilitation applications. Our existing products and those in development create major global opportunities for growth.
Prothia accompanies clinicians to assist them in reaching their therapeutic and diagnostic objectives. Listening attentively defines us. We strive to be useful and to do what we do well.
We have acquired knowledge and created intellectual property over the years and seek to adapt ourselves to the world’s premier market in our areas of specialization: cardiology, obstetrics and rehabilitation.
For more information, please contact us at phone number +1.774.502.8409 or email us at firstname.lastname@example.org
Time Bioscience is hybrid biotech company founded by Tom Shi, Ph.D. and Martha Hadeler, MBA. The company manufactures signaling transduction proteins, signaling specific reporter cell lines, and drug screening kits. The company also provides custom protein manufacturing, animal model services, as well as drug screening services.
Liang Yang, Ph.D
President & CEOylbiodetail@gmail.com
Bio-Detail Corporation is a startup company focus on virus construction, package and stereotaxic injection. We provide service of sub cloning target gene or their shRNA into AAV and lenti virus backbone, package virus, and stereotaxic intracranial injection into mouse and rat.
Edward Ginns, M.D., Ph.D
President and CSOeginns@targetedcelltherapies.us
Targeted Cell Therapies (TCT) is an early-stage Massachusetts-based biotechnology company commercializing a powerful technology platform for the oral delivery of therapeutics. Our technology represents a paradigm shift for the delivery of large molecule therapeutics, enabling oral administration and avoiding the need for injection. Formulations consist of ingestible yeast glucan particles containing therapeutic nucleic acid (nanoplexed DNA or RNA) or protein payload molecules that are selectively taken up by intestinal macrophages. The glucan particle payloads are processed by cellular machinery into active therapeutics as the macrophages migrate to sites of inflammation or pathology in tissues throughout the body. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets include low bone density conditions, metastatic bone disease and inflammatory disorders. By combining macrophage targeting with payload versatility, our technology platform has the potential to offer strategic advantages, including improved efficacy and safety, in the delivery of large molecule therapeutics for a broad range of human conditions.
Monty Montano, Ph.D.
President & Foundermmontano@myosyntax.com
MyoSyntax uses compelling technology to address the growing need for muscle health by enabling individuals to optimize their muscle growth, maintain muscle mass and prevent muscle loss.
Welgen, Inc. is a biotech company dedicated to developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. Our products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.
Dr. David Tabatadzeinfo@zatapharmaceuticals.com
ZATA is focused on two major programs: 1) ZAP-D – Current blood safety approach is based on a large number of tests that do not provide 100% safety. ZAP-D (synthetic compound_ provides full safety by selective elimination of genomic molecules of the pathogens if presented in donated blood. 2) ZATA’S OLIGOTHERAPEUTICS (OT). Cell membranes do not allow for the cellular uptake of negatively charged OT currently used. Low cellular penetration caused multiple OT to fail over the last couple of decades. ZATA’s technology solves this problem. For investment or collaboration opportunity write to Dr. David Tabatadze:email@example.com.
Madhu S. Malo, MD, PhD
President & CEO
Atoxin Biotech, LLC (Atoxin) is a biotechnology company founded in 2014 by Madhu S. Malo, MD, PhD. Prior to starting the company, Dr. Malo served as an Assistant Professor at Harvard Medical School (Boston, MA). Atoxin aims to develop biomedical products and technologies that could be used in the USA, and also could be exported to the other countries, especially to the developing countries.
IOMICS is a leading-edge analytics company based in Worcester and Cambridge Massachusetts. IOMICS believes the freedom to explore new ideas and rapidly deploy advanced analytics is essential to accelerating science, designing safer consumer products, and improving healthcare. Through our award-winning software products and consulting services, IOMICS is driving a broad range of process-improvement initiatives and providing a sustainable business advantage to its clients and partners worldwide.
For the Latest News on IOMICS Corporation click here.
Prakash Kadkade, Ph.D.
President and CEOpkbiotechnic@aol.com
Janus Biotherapeutics is an autoimmunity therapeutics company dedicated to the development of novel, orally available compounds for the treatment of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, psoriasis, and scleroderma.
Dr. Prabu Nambiar
JuvoBio uses patient-specific or genetically engineered human induced pluripotent stem cells (iPSCs) and the various subtypes of neuronal cells derived from such iPSCs to build disease models for neurodevelopmental and neurodegenerative diseases. With advanced techniques including single-cell RNAseq, multiplexed deep sequencing, high-content imaging analyses and bioinformatics tools, JuvoBio has developed and is developing more high-throughput assays for identifying new biomarkers and therapeutics for neurological indications.
Or-Genix Therapeutics, Inc. is a near commercial stage company led by veterans of the pharmaceutical industry. Or-Genix is the exclusive licensee of scientifically validated locally acting topical products discovered at Yale Unversity for hormonally aged skin and mucous membranes.
SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nanosystems through the use of our revolutionary science and technologies, we offer high quality innovation, science and management expertise, encouraging results, an impressive IP portfolio, and growing involvement in international research.
Our pioneering research efforts focus on four core therapeutic areas: cancer, atherosclerosis, inflammatory and immune diseases.
HSRL was established with one goal in mind: To provide the highest quality services within budget and on time.
We have a passion for what we do. Each team member takes the time and consideration to ensure each study is given the time and attention it requires.
Our staff is committed to scientific integrity and superior responsiveness to client needs.
We provide our services to other Contract Research Organizations, drug discovery, biotechnology, medical device and pharmaceuticals companies, clinics, academic institutions and government agencies.